CLAIMS

1. Compounds of formula:



(I)

in which:

- $R_1$ represents hydrogen or a $(C_1-C_4)$alkyl;
- $R_2$ represents: . a $(C_3-C_7)$alkyl group,
  . an indan-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl group, said groups being unsubstituted or substituted by a halogen atom and/or a methyl group;
  . a saturated, single-nitrogen heterocyclic radical of 5 to 7 atoms, the nitrogen atom being substituted by a $(C_1-C_4)$alkyl, benzyl, $(C_1-C_3)$alkoxycarbonyl or $(C_1-C_4)$alkanoyl group;
  . a group $NR_9R_{10}$;
  . a group $(CH_2)_nR_{11}$, $CH(CH_3)R_{11}$, $(CH_2)_mN(CH_3)R_{11}$;
  . a $C_3-C_{12}$ nonaromatic carbocyclic

radical, unsubstituted or substituted one or more times by a methyl group;

- or $R_1$ and $R_2$ together with the nitrogen atom to which they are attached form either a piperazin-1-yl radical substituted in position 4 by a phenyl or benzyl group, or a piperidin-1-yl radical disubstituted in position 4 by a phenyl or benzyl group and by a $(C_1-C_4)$alkyl or $(C_1-C_3)$alkanoyl group; the phenyl or benzyl group substituents on the piperazin-1-yl radical or the piperidin-1-yl radical being unsubstituted or substituted by a halogen atom and/or a methyl group;
- $R_3$, $R_4$, $R_5$, $R_6$, $R_7$ and $R_8$ represent each independently of one another a hydrogen or halogen atom or a $(C_1-C_6)$alkyl, $(C_1-C_6)$alkoxy or trifluoromethyl group;
- $R_9$ and $R_{10}$ together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms containing or not containing a second heteroatom selected from O and N, said radical being unsubstituted or substituted one or more times by a $(C_1-C_4)$alkyl, hydroxyl or $(C_1-C_4)$alkoxy group;
- $R_{11}$ represents: . a phenyl which is unsubstituted or substituted by one or more substituents selected from a

halogen atom and a methyl group;

. a heteroaryl radical of 6 to 10 atoms containing one or more nitrogen atoms;

- n represents 1, 2 or 3;
- m represents 0, 2 or 3;

and their salts, their solvates and their hydrates.

2. A compound according to claim 1 of formula (I) in which:

- $R_1$ represents a hydrogen atom or a $(C_1-C_4)$alkyl group;
- $R_2$ represents a group $NR_9R_{10}$ or a nonaromatic $C_3-C_{12}$ carbocyclic radical which is unsubstituted or substituted one or more times by a methyl group;
- $R_3$, $R_4$, $R_5$, $R_6$, $R_7$ and $R_8$ represent each independently of one another a hydrogen or halogen atom or a $(C_1-C_6)$alkyl, $(C_1-C_6)$alkoxy or trifluoromethyl group;
- $R_9$ and $R_{10}$ together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic radical of 5 to 10 atoms, containing or not containing a second heteroatom selected from O and N, said radical being unsubstituted or substituted one or more times by a $(C_1-C_4)$alkyl group;

and their salts, their solvates and their hydrates.

3. Compounds according to claim 1 or claim

2 of formula (I) in which:

- $R_1$ represents a hydrogen atom; and/or
- $R_2$ represents a group selected from piperidin-1-yl, pyrrolidin-1-yl, cyclohexyl, spiro[5.5]undecanyl and 1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl; and/or
- at least one of the substituents $R_3$, $R_4$ and $R_5$ represents a halogen atom or a trifluoromethyl group; and/or
- at least one of the substituents $R_6$, $R_7$ and $R_8$ represents a halogen atom.

4. A process for preparing a compound of formula (I) according to any one of claims 1 to 3, characterized in that a functional derivative of terphenylic acid of formula:




(II)

in which $R_3$, $R_4$, $R_5$, $R_6$, $R_7$ and $R_8$ are as defined for a compound of formula (I) in claim 1 is treated with an amine of formula $HNR_1R_2$ (III) in which $R_1$ and $R_2$ are as defined for a compound of formula (I) in claim 1.

5. Compounds of formula:




(IIa)

in which $R_3$, $R_4$, $R_5$, $R_6$, $R_7$ and $R_8$ are as defined for a compound of formula (I) in claim 1 and R represents a hydrogen atom or a $(C_1-C_4)$alkyl group, on condition that $R_3$, $R_4$, $R_5$, $R_6$, $R_7$ and $R_8$ are not simultaneously hydrogen, and on condition that, when $R_4$, $R_5$, $R_7$ and $R_8$ represent hydrogen, $R_3$ and $R_6$ do not simultaneously represent a fluorine atom in meta position, or a methoxy group in meta or para position, and on condition that when $R_5$ and $R_8$ represent hydrogen $R_3$, $R_4$ and $R_5$, $R_6$ do not simultaneously represent 3,4-dimethoxy groups.

6. A compound according to claim 5 of formula (IIa) in which:

- $R_3$ is in position 4 and represents a halogen atom or a trifluoromethyl group;
- $R_6$ is in position 2 and represents a hydrogen or halogen atom;
- $R_7$ is in position 4 and represents a halogen atom;
- $R_4$, $R_5$ and $R_8$ are hydrogen.

7. A medicinal product characterized in that it comprises a compound of formula (I) according

to any one of claims 1 to 3, or one of its pharmaceutically acceptable salts, hydrates or solvates.

8. A pharmaceutical composition characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 3, or one of its pharmaceutically acceptable salts, hydrates or solvates, and at least one pharmaceutically acceptable excipient.

9. The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended for treating any disease involving the $CB_1$ cannabinoid receptor.

10. The use of a compound of formula (I) according to any one of claims 1 to 3 for preparing a medicinal product intended for treating psychotic disorders, memory and cognitive disorders, appetite disorders and obesity, or for tobacco withdrawal or alcohol withdrawal.